XDH and hyperuricemia: The current standard for therapy of hyperuricemia-related diseases considers either an uricostatic strategy, i.e. inhibition of xanthine oxidase to reduce uric acid production, or an uricolytic approach, exploiting intravenous administration of PEGylated Uox to favor the conversion of insoluble urate to HIU.